Updates

These updates includes material published by third parties and compiled by PAHO. PAHO has taken reasonable precautions to verify the information contained in the document. However, this material is being distributed without warranty of any kind. The reader is responsible for the interpretation and use of this information and in no event shall PAHO be held liable for any damages arising from its use.
  • Updates
  • Official reports from pharmacovigilance programs
  • Clarifications/conclusions of events presented in previous communications
  • Other related updates
03/31/2021

Possible explanation of rare prothrombotic events with the AstraZeneca vaccine in Europe

There are press releases and communiqués, though no published studies, stating the following: In response to reports that emerged after a few recipients of the AstraZeneca COVID-19 vaccine...

Read more
03/31/2021

GACVS statement on rare thrombotic events with the AstraZeneca vaccine in Europe

The COVID-19 subcommittee of the Global Advisory Committee on Vaccine Safety (GACVS) met in March 2021 to review available data on cases of thromboembolism and thrombocytopenia reported following administration of the AstraZeneca COVID-19 vaccine.

Read more
03/30/2021

Vaccination and patients with long-term symptoms

There are a number of patients with COVID-19 who develop long-term symptoms after infection with SARS-CoV-2, for which the term "Long COVID" has begun to be used. The symptoms vary, but the most common are fatigue, shortness of breath, myalgia, and insomnia.

Read more
03/30/2021

Influenza-like illness after administration of COVID-19 vaccines

The Global Advisory Committee on Vaccine Safety (GACVS) of the World Health Organization (WHO) reviewed clinical trial data and a summary of reports of influenza-like illnesses following COVID-19 vaccination, drawn from the WHO Global Database of Individual Case Safety Reports (VigiBase).

Read more
03/23/2021

New vaccines development

The emergence of variants with the ability to evade the immune system is driving a search for new development strategies and expanding the range of viral epitopes, which the new vaccines are designed to address.

Read more